Wave Life Sciences, Inc. WVE
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Wave Life Sciences, Inc. (WVE) is a healthcare company listed in the US with a market value of about $617M. In the twelve months to September 30, 2026 it had revenue of $71M and net income of -$211M, a net margin of -296.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 16% a year, a 5-year average ROIC of -96%.
About Wave Life Sciences
Wave Life Sciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $152000 in 2015 to $43M in 2025, growth of about 75.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 114% over three years (dilution for shareholders). It spends 428% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $43M | $108M | $113M | $4M | $41M | $20M | $16M | $14M | $4M | $1M |
| Net income | -$211M | -$204M | -$97M | -$58M | -$162M | -$122M | -$150M | -$194M | -$147M | -$102M | -$56M |
| Free cash flow | -$208M | -$188M | -$152M | -$21M | -$129M | -$90M | -$117M | -$192M | -$33M | -$103M | -$37M |
| EPS (diluted) | $-1.06 | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 | $-3.82 | $-5.72 | $-5.06 | $-3.85 | $-2.44 |
| Net margin | -296.9% | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | -746.7% | -1211.5% | -1017.4% | -2619.6% | -3748.1% |
| ROIC | — | -40.2% | -47.0% | -93.7% | — | -203.2% | -136.1% | -216.4% | -115.9% | -57.9% | -32.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $16.63, 431% above the current price; targets range from $10.00 to $44.00; the consensus rating is “Strong buy”; expected EPS is $-1.10 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Wave Life Sciences pay a dividend?
Not currently.
Is Wave Life Sciences a good stock to buy?
We do not give buy or sell advice. Wave Life Sciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.